Institut Pasteur

Other

Aventis Pharma S.a.

Institut Pasteur and Centre National De La Recherche Scientifique

Centre National De La Recherche Scientifique

Olivier Danos

Philippe Moullier

Jean-Michel Heard

Pierre Sonigo

Marc Alizon

Simon Wain-Hobson

Jean-Claude Chermann

Stewart T Cole

Solange Chamaret

Bernard Krust

Nicolas Ferry

Luc Montagnier

Michel Perricaudet

Francoise Barre-Sinoussi

William Vainchenker

Cole Stewart

Yves Beuzard

Fran&ccedil;ois Clavel

Francedillaois Clavel

François Clavel

Nadia Naffakh

Vincent Descamps

Luc Montangnier

Fran&ccedil;oise Barre-Sinoussi

Francedillaoise Barre-Sinoussi

Michael Katinka

Moshe Yaniv

Françoise Barre-Sinoussi

The present invention provides cell compositions for in vivo implantation, and designed for the sustained and controlled delivery of therapeutic substances.

Composition for the in vivo production of therapeutic products

The molecular cloning and characterization of a novel human retrovirus, designated lymphadenopathy-associated virus, or LAV, is disclosed. LAV was originally isolated from a patient with acquired immune deficiency syndrome (AIDS). A cloned LAV complementary DNA (cDNA) was used to screen a library of recombinant phages constructed from the genomic DNA of LAV-infected T lymphocytes. The nucleotide sequence of an insert obtained from the recombinant phage clone &lgr;J19 was ascertained through M13 shotgun cloning and the dideoxy chain termination sequencing method. The env coding region was identified and various hydrophilic peptides obtained therefrom. These peptides correspond to amino acids 551-577, 594-603, 621-630, 657-679, and 719-758 of the LAV envelope glycoprotein. These peptides should provide suitable diagnostic reagents for the detection LAV-specific antibodies and for the generation of LAV-specific immunological reagents.

Nucleic acids and peptides of human immunodeficiency virus type (HIV-1)

The invention relates to an implant obtained by assembling in vitro various elements in order to form a neo-organ which is introduced preferably in the peritoneal cavity of the recipient. The implant comprises a biocompatible support intended to the biological anchoring of cells; cells having the capacity of expressing and secreting naturally or after recombination a predetermined compound, for example a compound having a therapeutical interest; and a constituent capable of inducing and/or promoting the geling of said cells. The invention also relates to a kit for the preparation of the implant as well as to a new recombinant retroviral vector comprising a provirus DNA sequence modified in that the genes gag, pol and env have been deleted at least partially so as to obtain a proviral DNA capable of replication. The invention also relates to recombinant cells comprising the new retroviral vector.

Recombinant retroviral vector

Biocompatible implant for the expression and in vivo secretion of a

This invention is directed to nucleic acids derived from the pol region of the genome of human immunodeficiency virus type 1 (HIV-1). The nucleic acids are useful as probes for the detection of HIV-1. More particularly, this invention is directed to nucleic acids encoding a pol region of HIV-1 extending from about nucleotide 1856 to about 1906 and extending from about nucleotide 2048 to about nucleotide 2797.

Nucleic acids and pepties of human immunodeficiency virus type-1 (HIV-1).

DNA Fragments coding for polypeptides containing at least one antigenic

Growing community of inventors

Garches, France

Olivier Danos